PubMed Health⌕ Search

Biomedical subjects

Sally G Haskell

Publications and source records attributed to Sally G Haskell.

8 recordsLinked to original sources

Full-body skin examinations and the female veteran: prevalence and perspective.

OBJECTIVES: To determine the frequency of full-body skin examinations (FBSEs) among female veterans and to determine whether patient risk factors for skin cancer alter the frequency of screening. Subjects were also queried as to attitudes about FBSE. DESIGN: Questionnaires pertaining to whether patients underwent regular FBSE, their opinions and attitudes about this screening test, and their risks for developing skin cancer. SETTING: A primary health care clinic for female veterans at a Veterans Affairs medical center. PARTICIPANTS: A convenience sample of 245 patients awaiting clinic appointments. Of those asked to participate, 201 agreed, for a participation rate of 82%. MAIN OUTCOME MEASURES: Patient report of undergoing FBSE, attitudes regarding FBSE, and risk factors for cutaneous malignancy. RESULTS: Eighteen percent of all respondents reported undergoing regular FBSE by their primary care provider, whereas 9 (45%) of the 20 with a history of skin cancer reported undergoing FBSE. Fifteen percent of subjects reported embarrassment with FBSE. Seventy-nine percent reported that their primary care provider would be considered thorough by performing FBSE, and 69% would like their primary care provider to perform FBSE regularly. We found that 16% of subjects would refuse the examination if the primary care provider were of the opposite sex, whereas 38% would not refuse but be less willing to be examined. CONCLUSIONS: Female veterans report a low incidence of FBSE, although those with a personal history of skin cancer are more likely to undergo screening. Despite embarrassment expressed about a sex difference between the patient and examiner, female veterans have a strong preference to undergo FBSE.

Adult↗

The prevalence and age-related characteristics of pain in a sample of women veterans receiving primary care.

BACKGROUND: Women veterans are a growing but understudied population believed to be at increased risk for pain problems. Because of risk factors and clinical observations, we hypothesized that women veterans might have a high prevalence of pain and, thus, sought to determine the prevalence of (and age-related variations in) pain and to characterize several key pain dimensions in a sample of women veterans. METHODS: Women with routine appointments at the VA Connecticut Women's Health Center were recruited for study. Participants completed a 59-item questionnaire that provided information about their demographic, clinical, and pain status, as well as use of health services. RESULTS: Of 236 women approached, 213 (89%) completed the questionnaire. The mean age was 52 years, and most (78%) reported an ongoing pain problem. For those reporting pain, the mean duration of pain was 6 years, average pain intensity was 6.3 (range 1-10), and commonly endorsed pain sites included lower extremity (68%), low back (63%), and shoulder (48%). The most frequently endorsed treatment (by 80%) was analgesic medication use. Across the four age categories (20-35, 36-50, 51-65, and > or =66 years), pain prevalences were 64%, 89%, 83%, and 69%, respectively. Although pain intensity levels did not vary across age groups, older women (> or =66) reported using fewer pain treatments, including analgesic medications. Finally, those with (vs. those without) pain reported a greater number of medical and mental health visits in the preceding year. CONCLUSIONS: This study documented a significantly high prevalence of pain among a sample of women veterans receiving primary care in a VA women's health clinic.

Adult↗

Update in thrombosis: answers to perplexing questions.

Recent clinical trials are answering some of the perplexing clinical questions about venous thromboembolism (VTE), such as the length and intensity of anticoagulation needed to prevent recurrence. We review some of these clinical trials and their implications for physicians and patients.

Anticoagulants↗

After the Women's Health Initiative: Postmenopausal women's experiences with discontinuing estrogen replacement therapy.

OBJECTIVE: To gather information about women's responses to the publication of the Women's Health Initiative (WHI) and to determine what proportion of women stopped hormone replacement therapy (HRT) and whether the technique of discontinuation affected the recurrence of menopausal symptoms. METHODS: 73 subjects were identified through VA pharmacy records and were mailed a letter detailing the results of the WHI. A follow-up questionnaire was mailed several months later to the same population. RESULTS: 48 subjects responded and were eligible for inclusion in the study. Mean age was 62 years; 37 (77%) stopped taking HRT, and 11 (23%) continued. Twenty patients stopped abruptly, and 17 tapered off HRT. Eight (40%) of the group who stopped abruptly experienced recurrent menopausal symptoms, compared with 12 (71%) of the group who tapered HRT. CONCLUSIONS: In a population of women veterans, 77% stopped HRT after publication of the WHI. Tapering HRT, rather than stopping abruptly, did not reduce the recurrence of menopausal symptoms in our patient population.

Aged↗

A novel program to increase the number of women patients seen by residents in a VA hospital.

A recent requirement from the Accreditation Council for Graduate Medical Education that internal medicine residents must provide care for a minimum of 25% of female patients in their longitudinal clinics has posed difficulties for Internal Medicine programs that utilize Department of Veterans Affairs (VA) hospitals for outpatient training. The authors report an innovative program developed at a Connecticut VA hospital for internal medicine residents at the Yale University School of Medicine. Residents participate in the clinic at the VA Women's Health Center every fourth week instead of attending their usual VA primary care clinic. To increase the numbers of patients being seen by residents, the "Sharing Program" was initiated in 2001 so that wives of veterans could be seen in the VA women's clinic. Sharing Program patients are billed for their care by the Yale University Medical Group and the VA is reimbursed by the University Medical Group for the cost of providing care to these patients. As a result of the Sharing Program, the mean proportion of female patients assigned to residents has reached 25%. Surveys showed high levels of patient and resident satisfaction, and that residents perceived an improvement in their education in the outpatient care of women.

Connecticut↗

Selective estrogen receptor modulators.

Because of recent concerns about the long-term risks of estrogen replacement therapy in postmenopausal women, there is growing interest in a group of compounds known as selective estrogen receptor modulators (SERMs). The SERMs bind to estrogen receptors and have tissue-specific effects that allow them to function as estrogen agonists in some tissues and estrogen antagonists in other tissues. There are four SERMs currently marketed in the United States. These include the triphenylethylenes--clomiphene citrate (Clomid), tamoxifen, and toremifene--and the benzothiophene, raloxifene. Clomid is used primarily in the treatment of infertility. Tamoxifen is indicated for the treatment and prevention of breast cancer. It has an estrogen antagonist effect on breast tissue, but an estrogen-like effect on lipids, bone, and the endometrium. Toremifene has an antagonist/agonist profile similar to that of tamoxifen. Raloxifene is approved for the prevention of osteoporosis in postmenopausal women. It is thought to be an estrogen antagonist on the uterus and breast tissues and an estrogen agonist with respect to bone and serum lipids.

Bone and Bones↗

The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial.

To determine whether treatment with raloxifene has a beneficial effect on cognitive function in postmenopausal women, 50 postmenopausal women were randomized to receive raloxifene 60 mg, or placebo, for eight weeks. Participants completed pre- and post-treatment assessment of cognitive and psychological function including the Beck Anxiety and Beck Depression inventories, the SF-36 Scale of physical and emotional well-being, five tests of cognitive function including Block Design and Digit Span subtests of the Wechsler Adult Intelligence Scale-III (WAIS-III), the Logical Memory and Paired Associates subtests of the Wechsler Memory Scale-III, and the Digit Cancellation test. Results showed no significant effect attributable to eight weeks of treatment with raloxifene on cognitive, psychological, or health variables.

Aged↗